Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,500 shares, a drop of 23.9% from the August 31st total of 13,800 shares. Based on an average trading volume of 40,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the shares of the company are sold short.

Theratechnologies Trading Up 5.0 %

Theratechnologies stock traded up $0.06 on Friday, reaching $1.25. 17,055 shares of the stock were exchanged, compared to its average volume of 44,874. Theratechnologies has a twelve month low of $0.88 and a twelve month high of $2.58. The firm has a fifty day moving average price of $1.33 and a two-hundred day moving average price of $1.34. The stock has a market cap of $57.48 million, a PE ratio of -6.37 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last posted its quarterly earnings data on Wednesday, July 10th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.04. The business had revenue of $22.02 million for the quarter. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities analysts anticipate that Theratechnologies will post -0.02 EPS for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.